¼ò
¤™
- ¼ò
- ·±
- EN
-
¹ØÓÚÎÒÃÇ ¤™
-
¿Æ¼¼´´Ð ¤™
-
²úÆ·ÓëÒµÎñ ¤™
-
ÐÂÎÅÖÐÐÄ ¤™
-
Ͷ×ÊÕß¹Øϵ ¤™
-
ESG ¤™
-
Ö°Òµ·¢Õ¹ ¤™
¼ò
¤™
- 2026Äê3ÔÂ12ÈÕ£¬Öйúҽѧ¿ÆѧԺÖ×ÁöÒ½ÔºÍõ½à½ÌÊÚÍŶÓǣͷ¿ªÕ¹µÄÓÉÑо¿Õß·¢ÆðµÄACROSS 2Ñо¿£¬ÕýʽÔÚÏß·¢±íÓÚ¹ú¼Ê¶¥¼âÖ×ÁöѧÆÚ¿¯¡¶CA: A Cancer Journal for Clinicians ¡·(Ó°ÏìÒò×Ó232.4) £¬ÎªEGFRÑôÐÔ¹²Í»±ä·ÇСϸ°û·Î°©£¨NSCLC£©¾«×¼ÖÎÁÆÊ÷Á¢È«ÐÂÑÖ¤±ê¸Ë£¡
×÷ΪÃÀ¹ú°©Ö¢Ñ§»áÖ÷°ìµÄȨÍþѧÊõÆÚ¿¯£¬¡¶CA: A Cancer Journal for Clinicians¡·³¤ÆÚÎȾÓÈ«ÇòÆÚ¿¯Ó°ÏìÒò×Ó°ñÊ×£¬ÒÔÑÏ¿ÁµÄͬÐÐÆÀÒé¡¢¼«¸ßµÄÁÙ´²Ö¸µ¼¼ÛÖµÖø³Æ¡£×÷ΪȫÇòÊ׸ö¾Û½¹EGFR+ÓëÒÖ°©»ùÒò¹²Í»±äNSCLCµÄ¢óÆÚÁÙ´²Ñо¿£¬ACROSS 2Ñо¿´Ë´ÎÈٵǸÿ¯£¬¼ÈÊÇÖйú·Î°©¾«×¼ÕïÁÆÑо¿µÄÖØҪͻÆÆ£¬¸üÊǹú²úÔÑÐÈý´úEGFR-TKI°¢ÃÀÀÖ?£¨¼×»ÇËá°¢ÃÀÌæÄáƬ£©ÁÙ´²¼ÛÖµ»ñµÃ¹ú¼ÊÈϿɵÄÓÖÒ»Àï³Ì±®£¬ÕÃÏÔÁËÖйúѧÕßǣͷÁÙ´²Ñо¿µÄÓ²ºËʵÁ¦ÓëÖйú´´ÐµÏÍþ¹ú¼ÊµÄÈ«Çò¾ºÕùÁ¦¡£
ÁÙ´²Í´µã£º
¹²Í»±ä¡¸Ä§Ö䡹£¬ÖÆÔ¼EGFR°ÐÏòÖÎÁÆ»ñÒæ
EGFRÍ»±äÊÇÑÇÖÞ·ÎÏÙ°©»¼ÕßÖÐ×î³£¼ûµÄÇý¶¯»ùÒòÍ»±äÀàÐÍ£¬·¢ÉúÂʸߴï40%-60%¡£¾¡¹ÜµÚÈý´úEGFR-TKI£¨Èç°¢ÃÀÌæÄᣩһÏßÖÎÁÆ¿Éʹ»¼ÕßÖÐλÎÞ½øÕ¹Éú´æÆÚ£¨mPFS£©´ï18-20¸öÔ£¬µ«Ëæ×Ŷþ´ú²âÐò£¨NGS£©µÄ¹ã·ºÓ¦Óã¬Ñо¿·¢Ïָߴï92.9%µÄ»¼ÕßЯ´ø²»Í¬ÀàÐ͵Ĺ²Í»±ä¡£ÆäÖУ¬ÒÔTP53Ϊ´ú±íµÄÖ×ÁöÒÖ°©»ùÒò£¨TSG£©¹²Í»±ä×îΪ³£¼û¡£
ÕæʵÊÀ½çÖУ¬EGFR Í»±äNSCLCºÏ²¢ TP53 ¹²Í»±äµÄ±ÈÀýΪ 40%-68%¡£ÕâÀ๲ͻ±äÖ×Áöͨ³£ÇÖÏ®ÐÔÇ¿¡¢½øÕ¹¸ü¿ì£¬¶Ô°ÐÏòµ¥µÏÍþ¹ú¼ÊÖÎÁƵÄÓ¦´ð³ÖÐøʱ¼ä¸ü¶Ì£¬ÊÇÁÙ´²Ø½´ýÍ»ÆƵÄÖÎÁÆÄÑÌâ¡£
ΪʵÏÖ¾«×¼ÖÎÁÆ¡¢Ã÷È·ÕæÕý»ñÒæÈËȺ£¬Íõ½à½ÌÊÚÍŶÓÉè¼Æ²¢¿ªÕ¹ÁËÁ½ÏîIIIÆÚÑо¿£ºACROSS 1£¨Õë¶ÔºÏ²¢EGFRÑôÐԺϲ¢Ô°©»ùÒò¹²Í»±äÈËȺ£©ºÍACROSS 2£¨Õë¶ÔºÏ²¢TSG¹²Í»±äÈËȺ£©¡£ÆäÖУ¬ACROSS 2Ñо¿ÊÇÊ׸öרÃÅÕë¶Ô°éÓÐTSG¹²Í»±äµÄEGFRÑôÐÔNSCLC»¼Õß¿ªÕ¹µÄÇ°Õ°ÐÔ¡¢Ëæ»ú¡¢¶àÖÐÐÄIIIÆÚÁÙ´²ÊÔÑé¡£¸ÃÑо¿ÎªÕâÒ»Ìض¨ÈËȺÌṩÁ˾ßÓÐÃ÷È·ÁÙ´²Ö¸µ¼¼ÛÖµµÄÑÖ¤Ö¤¾Ý£¬Ö§³ÖÔÚ¾«×¼ÈËȺÖÐʵʩǿ»¯Ò»ÏßÖÎÁƲßÂÔ¡£
°Ð»¯ÁªºÏ£º
¸ü¾«×¼µÄ»ñÒæ¸ÄÉÆ֮·
ACROSS 2Ñо¿¹²Èë×é126Àý»¼Õߣ¬´ÓÆô¶¯¡¢»¼ÕßËæ·Ãµ½Ñо¿½á¹û·¢±í£¬ÕûÌåÀúʱԼ4Äê¡£
ͨ¹ý½«»ùÒò·Ö²ãϵͳÐÔµØÕûºÏµ½Ò»ÏßÖÎÁƾö²ßÖУ¬ACROSS 2Ñо¿²ûÃ÷ÁËÈçºÎÐͬӦÓðÐÏòÖÎÁÆÓëϸ°û¶¾ÐÔÖÎÁÆ£¬ÒÔÓ¦¶ÔEGFRÍ»±äNSCLCËù³ÊÏֵĻùÒò×鸴ÔÓÐÔ¡£Ñо¿½á¹ûÏÔʾ£¬Óë°¢ÃÀÌæÄáµ¥µÏÍþ¹ú¼ÊÖÎÁÆÏà±È£¬°¢ÃÀÌæÄáÁªºÏ¿¨²¬-ÅàÃÀÇúÈû·½°¸¿É´øÀ´Í³¼ÆѧÏÔÖøÇÒ¾ßÓÐÁÙ´²ÒâÒåµÄPFS¸ÄÉÆ¡£
´ËÍ⣬ACROSS 2Ñо¿Îª½¨Á¢Ç°Õ°ÐԵķÖ×Ó·ÖÕïÁ÷³Ìµì¶¨ÁËÖØÒª»ù´¡£¬ÓÐÖúÓÚÉîÈ뾫׼ÖÎÁÆ£¬ÓÅ»¯ÖÎÁÆ»ñÒæ¡£¸ÃÖÎÁƲßÂÔÔÚ³£¹æÁÙ´²Êµ¼ùÖеÄÍƹãʵʩ£¬¸ß¶ÈÒÀÀµÓڹ㷺¡¢¹æ·¶µÄ¶à»ùÒòNGS¼ì²â×÷ΪǰÌá¡£
×÷ΪÖйúÊ׸öÔÑÐÈý´úEGFR-TKI£¬°¢ÃÀÀÖ?×Ô2020ÄêÉÏÊÐÒÔÀ´£¬Æ¾½èÓÅÒìµÄÁÆЧ¡¢Á¼ºÃµÄ°²È«ÐÔ¡¢ÔúʵµÄÑÖ¤Ö¤¾Ý£¬ÒÑÀۼƻñµÃ¹ú¼ÒµÏÍþ¹ú¼ÊÆ·¼à¶½¹ÜÀí¾ÖÅú×¼ÎåÏîÊÊÓ¦Ö¢£¬¸²¸ÇÍíÆÚÒ»Ïß¡¢¶þÏß¡¢Êõºó¸¨Öú¡¢¾ÖÍíÆÚ·Å»¯Áƺóά³ÖÖÎÁƵȺËÐÄÖÎÁƳ¡¾°£¬ÆäÖал¯ÁªºÏÊÊÓ¦Ö¢£¨°¢ÃÀÀÖ?ÁªºÏÅàÃÀÇúÈûºÍ²¬À໯ÁƵÏÍþ¹ú¼ÊÎÒÑÓÚ2026Äê1ÔÂÉÏÊС£
´Ë´ÎACROSS 2Ñо¿Æ¾½èÍ»ÆÆÐÔµÄÊý¾Ý·¢±íÓÚ¶¥¿¯CA£¬½øÒ»²½º»ÊµÁË°¢ÃÀÀÖ?ÔÚEGFRÑôÐÔ¹²Í»±äÈËȺÖеÄÖÎÁƵØλ£¬ÎªÁÙ´²ÌṩÁ˸ü¾«×¼¡¢¸ü¸ßЧµÄÒ»ÏßÖÎÁƲßÂÔ£¬½«ÖúÁ¦·Î°©¾«×¼ÖÎÁÆÉý¼¶£¬»Ý¼°¸ü¶à·Î°©»¼Õß¡£
¹ØÓÚ°¢ÃÀÀÖ?
°¢ÃÀÀÖ?£¨¼×»ÇËá°¢ÃÀÌæÄáƬ£©ÊÇÖйúÊ׸öÔÑÐÈý´úEGFR-TKI£¬¾ßÓÐÁ¼ºÃµÄÖ¬ÈÜÐÔºÍÎȶ¨ÐÔ£¬ÄܸüºÃµØ͸¹ýѪÄÔÆÁÕÏ£¬ÇÒ²»Á¼·´Ó¦·¢ÉúÂʵ͡£Ä¿Ç°£¬°¢ÃÀÌæÄáÒÑÓÐÎåÏîÊÊÓ¦Ö¢»ñNMPAÅú×¼ÉÏÊУ¬·Ö±ðÊÇ£º¶þÏßÖÎÁƼÈÍù¾EGFR-TKIÖÎÁƽøÕ¹£¬ÇÒT790MÍ»±äÑôÐԵľֲ¿ÍíÆÚ»òתÒÆÐÔNSCLC»¼Õߣ»Ò»ÏßÖÎÁƾßÓÐEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äÑôÐԵľֲ¿ÍíÆÚ»òתÒÆÐÔNSCLC³ÉÈË»¼Õߣ»º¬²¬¸ùÖÎÐÔ·Å»¯Áƺóδ³öÏÖ¼²²¡½øÕ¹µÄ²»¿ÉÇгýµÄ¾Ö²¿ÍíÆÚEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äµÄNSCLC»¼ÕßÖÎÁÆ£»ÓÃÓÚ¢ò-¢óBÆÚ¾ßÓÐEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äµÄ³ÉÈËNSCLC»¼ÕßµÄÖÎÁÆ£¬»¼ÕßÐë¼ÈÍù½ÓÊܹýÊÖÊõÇгýÖÎÁÆ£¬²¢ÓÉÒ½Éú¾ö¶¨½ÓÊÜ»ò²»½ÓÊܸ¨Öú»¯ÁÆ£»ÁªºÏÅàÃÀÇúÈûºÍ²¬À໯ÁƵÏÍþ¹ú¼ÊÎïÊÊÓÃÓÚ¾ßÓÐEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äµÄ¾Ö²¿ÍíÆÚ»òתÒÆÐÔNSCLC³ÉÈË»¼ÕßµÄÒ»ÏßÖÎÁÆ¡£
2025Äê6ÔÂ4ÈÕ£¬°¢ÃÀÌæÄáµ¥µÏÍþ¹ú¼ÊÖÎÁÆÁ½ÏîÊÊÓ¦Ö¢ÔÚÓ¢¹ú»ñÅúÉÏÊС£2025Äê12ÔÂ16ÈÕ£¬µÏÍþÖƵÏÍþ¹ú¼ÊÊÚÓè Glenmark °¢ÃÀÌæÄá¶àÇøÓò¶À¼ÒȨÒæ¡£2026Äê2ÔÂ12ÈÕ£¬°¢ÃÀÌæÄáµ¥µÏÍþ¹ú¼ÊÖÎÁÆÁ½ÏîÊÊÓ¦Ö¢ÔÚÅ·ÃË»ñÅúÉÏÊС£
1. Duan J C, Zhong J, Sun B Y, et al. Aumolertinib with carboplatin¨Cpemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study[OL]. CA Cancer J Clin. Published online March 12, 2026.doi:10.3322/caac.70071.
2. Gunturu KS, Khan H, de Lima Lopes G Jr. Targeting tumor suppressor gene co-mutations in EGFR-mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification. CA Cancer J Clin. Published online March 12, 2026. doi:10.3322/caac.70072
¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê
ÃâÔðÉùÃ÷
Ç°Õ°ÐÔ˵Ã÷
